Skip to main content

Analysts Conflicted on These Healthcare Names: NeoGenomics (NEO), Labcorp Holdings (LH) and Cogent Biosciences (COGT)

Tipranks - Tipranks - Thu Feb 19, 6:44AM CST

Analysts have been eager to weigh in on the Healthcare sector with new ratings on NeoGenomics (NEO – Research Report), Labcorp Holdings (LH – Research Report) and Cogent Biosciences (COGT – Research Report).

President's Day Sale - 70% Off

NeoGenomics (NEO)

BTIG analyst Mark Massaro reiterated a Hold rating on NeoGenomics today. The company’s shares closed last Tuesday at $11.44.

According to TipRanks.com, Massaro has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -4.0% and a 33.7% success rate. Massaro covers the Healthcare sector, focusing on stocks such as BillionToOne, Inc. Class A, Adaptive Biotechnologies, and Tempus AI, Inc. Class A. ;'>

Currently, the analyst consensus on NeoGenomics is a Moderate Buy with an average price target of $14.75, a 40.5% upside from current levels. In a report released today, TipRanks – Google also downgraded the stock to Hold with a $12.00 price target.

See today’s best-performing stocks on TipRanks >>

Labcorp Holdings (LH)

In a report released today, Ann Hynes from Mizuho Securities reiterated a Buy rating on Labcorp Holdings, with a price target of $320.00. The company’s shares closed last Tuesday at $276.67.

According to TipRanks.com, Hynes is a 4-star analyst with an average return of 5.2% and a 54.8% success rate. Hynes covers the Healthcare sector, focusing on stocks such as Concentra Group Holdings Parent, Inc., BrightSpring Health Services, Inc., and Ardent Health Partners, Inc. ;'>

Currently, the analyst consensus on Labcorp Holdings is a Strong Buy with an average price target of $306.25, which is a 10.2% upside from current levels. In a report issued on February 6, J.P. Morgan also maintained a Buy rating on the stock with a $319.00 price target.

Cogent Biosciences (COGT)

Guggenheim analyst Michael Schmidt maintained a Buy rating on Cogent Biosciences yesterday and set a price target of $45.00. The company’s shares closed last Tuesday at $37.62.

According to TipRanks.com, Schmidt is a 5-star analyst with an average return of 30.0% and a 57.4% success rate. Schmidt covers the Healthcare sector, focusing on stocks such as ArriVent BioPharma, Inc., Monte Rosa Therapeutics, and Revolution Medicines. ;'>

Cogent Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $53.90, which is a 49.6% upside from current levels. In a report released yesterday, LifeSci Capital also maintained a Buy rating on the stock with a $55.00 price target.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).